GlassScriptPhysician profile
Matthew Cranford
NPI 1558307090
$6,840.60
in general payments reported to CMS, 2019-2025
32 companies · $980 in 2025
The $980 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,576 · 2020: $453 · 2021: $914 · 2022: $1,369 · 2023: $1,070 · 2024: $478 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,637.61 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,369.86 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Boston Scientific Corporation | $1,000.48 | 2019-2022 | |
| Pfizer INC. | $550.92 | 2019-2025 | |
| Qol Medical, LLC | $319.02 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $317.35 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $206.78 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.78 | 2019-2023 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $192.46 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $162.27 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $127.80 | 2019-2023 | Linzess |
| Covidien LP | $118.51 | 2019 | |
| Nestle Healthcare Nutrition INC. | $95.91 | 2022-2023 | |
| Medtronic, INC. | $68.99 | 2021 | |
| Shionogi INC | $58.39 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $56.39 | 2021-2023 | Rebyota |
| Celgene Corporation | $49.75 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $43.95 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $34.96 | 2021-2023 | Sutab |
| Ucb, INC. | $25.89 | 2019-2020 | |
| Dova Pharmaceuticals | $24.28 | 2019 | |
| Allergan, INC. | $22.89 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.28 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $20.18 | 2025 | Iqirvo |
| Shield Therapeutics INC | $19.58 | 2025 | |
| Intercept Pharmaceuticals, INC. | $18.35 | 2025 | |
| Shire North American Group INC | $17.22 | 2019 | |
| Capsovision, INC. | $15.54 | 2025 | Capsocam Plus |
| Aimmune Therapeutics, INC. | $15.28 | 2025 | Zenpep |
| Amgen INC. | $15.21 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $15.11 | 2019 | |
| Travere Therapeutics, INC. | $1.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cranford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.